KR20230169375A - Pedf-유래 짧은 펩타이드를 포함하는 조성물 및 그것의 사용 - Google Patents

Pedf-유래 짧은 펩타이드를 포함하는 조성물 및 그것의 사용 Download PDF

Info

Publication number
KR20230169375A
KR20230169375A KR1020237039829A KR20237039829A KR20230169375A KR 20230169375 A KR20230169375 A KR 20230169375A KR 1020237039829 A KR1020237039829 A KR 1020237039829A KR 20237039829 A KR20237039829 A KR 20237039829A KR 20230169375 A KR20230169375 A KR 20230169375A
Authority
KR
South Korea
Prior art keywords
xaa
amino acid
naturally occurring
occurring amino
misc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020237039829A
Other languages
English (en)
Korean (ko)
Inventor
프랭크 웬-치 리
콴인 카렌 린
여우-핑 차오
중-추안 호
Original Assignee
브림 바이오테크놀로지, 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브림 바이오테크놀로지, 인코퍼레이티드 filed Critical 브림 바이오테크놀로지, 인코퍼레이티드
Publication of KR20230169375A publication Critical patent/KR20230169375A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020237039829A 2016-10-07 2017-08-24 Pedf-유래 짧은 펩타이드를 포함하는 조성물 및 그것의 사용 Ceased KR20230169375A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662405522P 2016-10-07 2016-10-07
US62/405,522 2016-10-07
KR1020197012272A KR20190066030A (ko) 2016-10-07 2017-08-24 Pedf-유래 짧은 펩타이드를 포함하는 조성물 및 그것의 사용
PCT/US2017/048340 WO2018067244A1 (en) 2016-10-07 2017-08-24 Compositions comprising pedf-derived short peptides and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197012272A Division KR20190066030A (ko) 2016-10-07 2017-08-24 Pedf-유래 짧은 펩타이드를 포함하는 조성물 및 그것의 사용

Publications (1)

Publication Number Publication Date
KR20230169375A true KR20230169375A (ko) 2023-12-15

Family

ID=61831898

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237039829A Ceased KR20230169375A (ko) 2016-10-07 2017-08-24 Pedf-유래 짧은 펩타이드를 포함하는 조성물 및 그것의 사용
KR1020197012272A Ceased KR20190066030A (ko) 2016-10-07 2017-08-24 Pedf-유래 짧은 펩타이드를 포함하는 조성물 및 그것의 사용

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197012272A Ceased KR20190066030A (ko) 2016-10-07 2017-08-24 Pedf-유래 짧은 펩타이드를 포함하는 조성물 및 그것의 사용

Country Status (10)

Country Link
US (1) US11760784B2 (https=)
EP (1) EP3596104A4 (https=)
JP (2) JP7573967B2 (https=)
KR (2) KR20230169375A (https=)
CN (1) CN110312732A (https=)
AU (2) AU2017340245B2 (https=)
EA (1) EA037698B1 (https=)
IL (1) IL265796B2 (https=)
TW (1) TWI878203B (https=)
WO (2) WO2018067244A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7481261B2 (ja) * 2018-04-08 2024-05-10 ブリム バイオテクノロジー インク 腱治癒に対するｐｅｄｆ由来短鎖ペプチドの使用
US20210221862A1 (en) * 2018-04-08 2021-07-22 Brim Biotechnology, Inc. Application of pedf-derived short peptides in the treatment of osteoarthritis
EP3773493A4 (en) * 2018-05-04 2022-03-30 Brim Biotechnology, Inc. PEDF DERIVED PEPTIDES TO PROMOTE MEIBOMIUS GLAND REGENERATION AND THEIR USES
CN111632128B (zh) * 2019-02-14 2022-07-05 三凡生技研发股份有限公司 短链胜肽组合物在预防或治疗干眼症的应用
TWI759610B (zh) * 2019-06-27 2022-04-01 晶碩光學股份有限公司 具有角膜修護功能的眼用產品
TWI744683B (zh) * 2019-08-27 2021-11-01 台灣基督長老教會馬偕醫療財團法人馬偕紀念醫院 短合成胜肽及其治療視網膜退化性疾病和/或組織損傷的用途
AU2019463840B2 (en) * 2019-08-27 2023-03-09 Mackay Memorial Hospital Short synthetic peptide and their uses for treating retinal degenerative diseases and/or tissue injuries
IL291929B1 (en) * 2019-10-06 2026-02-01 Brim Biotechnology Inc Preparations including short peptides derived from PEDF and their uses
CN112206312A (zh) * 2020-11-19 2021-01-12 北京大学第三医院（北京大学第三临床医学院） 一种包含pedf的用于治疗干眼的药物组合物
CN115364199A (zh) * 2021-05-19 2022-11-22 远大医药（中国）有限公司 包含pedf衍生的短肽的组合物及其制备方法和用途
WO2023244618A1 (en) * 2022-06-13 2023-12-21 Brim Biotechnology, Inc. Compositions comprising pedf-derived short peptides for the treatment of dry eye diseases
TW202400628A (zh) * 2022-06-24 2024-01-01 全福生物科技股份有限公司 用於治療神經營養性角膜炎疾病之包含pedf衍生短肽之組合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451763B1 (en) * 1992-06-04 2002-09-17 The United States Of America As Represented By The Department Of Health And Human Services Retinal pigmented epithelium derived neurotrophic factor and methods of use
US6797691B1 (en) * 1997-07-23 2004-09-28 Northwestern University Methods and compositions for inhibiting angiogenesis
EP1684692A2 (en) * 2003-10-29 2006-08-02 The Johns Hopkins University Pigment epithelium-derived factor, novel biological activity and methods of use
WO2005089811A1 (en) * 2004-03-12 2005-09-29 Genvec, Inc. Materials for treating vascular leakage in the eye
EP1986676A4 (en) * 2006-02-15 2009-11-04 Univ Yale Inc COMPOSITIONS AND METHODS FOR USE OF PEDF (PIGMENT-BASED EPITHELIC DERIVED FACTOR) PEPTIDE FRAGMENTS
WO2009134339A2 (en) * 2008-04-29 2009-11-05 Monsanto Technology, Llc Genes and uses for plant enhancement
JP2013507373A (ja) * 2009-10-08 2013-03-04 ニューロテック ユーエスエー， インコーポレイテッド 被包された細胞ベースの送達系におけるｐｅｄｆの使用
EP2508196B1 (en) * 2011-03-23 2018-09-26 Mackay Memorial Hospital Use of PEDF-derived polypeptides for promoting stem cells proliferation and wound healing
TWI554521B (zh) * 2011-10-19 2016-10-21 台灣基督長老教會馬偕醫療財團法人馬偕紀念醫院 色素上皮衍生因子衍生之多胜肽於治療禿髮和／或毛髮脫色之用途
US9884012B2 (en) * 2012-08-09 2018-02-06 Mackay Memorial Hospital Use of PEDF-derived polypeptides for promoting muscle or tendon regeneration or arteriogenesis
CN104903346B (zh) * 2012-09-19 2019-04-09 财团法人台湾基督长老教会马偕纪念社会事业基金会马偕纪念医院 Pedf衍生的多肽在预防和/或缓和皮肤老化中的用途
KR101770252B1 (ko) * 2012-09-20 2017-08-22 맥케이 메모리얼 호스피탈 골관절염을 치료하기 위해 사용되는 pedf-유도 폴리펩티드의 용도
WO2015038891A2 (en) * 2013-09-13 2015-03-19 The Penn State Research Foundation Functional peptide analogs of pedf

Also Published As

Publication number Publication date
WO2018067217A3 (en) 2019-05-02
IL265796A (en) 2019-06-30
EP3596104A1 (en) 2020-01-22
TW201822785A (zh) 2018-07-01
AU2017340245A1 (en) 2019-05-23
JP2019533722A (ja) 2019-11-21
IL265796B1 (en) 2024-10-01
IL265796B2 (en) 2025-02-01
JP2022185042A (ja) 2022-12-13
WO2018067217A2 (en) 2018-04-12
KR20190066030A (ko) 2019-06-12
TWI878203B (zh) 2025-04-01
US20190248859A1 (en) 2019-08-15
CN110312732A (zh) 2019-10-08
EP3596104A4 (en) 2021-02-17
WO2018067244A1 (en) 2018-04-12
JP7573967B2 (ja) 2024-10-28
US11760784B2 (en) 2023-09-19
EA201990885A1 (ru) 2019-08-30
AU2017340245B2 (en) 2022-07-21
EA037698B1 (ru) 2021-05-12
AU2022204557A1 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
JP7573967B2 (ja) Ｐｅｄｆ由来短ペプチドを含む組成物およびその使用
Yang et al. The artemisinin analog SM934 alleviates dry eye disease in rodent models by regulating TLR4/NF-κB/NLRP3 signaling
Baudouin et al. In vitro and in vivo experimental studies on trabecular meshwork degeneration induced by benzalkonium chloride (an American Ophthalmological Society thesis)
Yang et al. 0.005% preservative-free latanoprost induces dry eye-like ocular surface damage via promotion of inflammation in mice
US20240123032A1 (en) Compositions and methods for prevention and treatment of corneal haze and scarring
JP2020038211A (ja) 眼の感染症および疾患を処置するための組成物および方法
Lin et al. Serine protease inhibitor A3K suppressed the formation of ocular surface squamous metaplasia in a mouse model of experimental dry eye
Li et al. Effects of topical mucolytic agents on the tears and ocular surface: a plausible animal model of mucin-deficient dry eye
AU2019262664B2 (en) PEDF-derived peptides for promoting meibomian gland regeneration and uses thereof
ES3025657T3 (en) Tsg6 polypeptide fragment for dry eye disease
KR102023827B1 (ko) 안구 건조증 질환의 치료 및/또는 예방을 위한 짧은 합성 펩티드의 용도
JP6779599B2 (ja) 角結膜障害治療剤
TW202228726A (zh) 一種醫藥組合物用於製備眼表損傷之藥物的用途
Kim et al. Protective Effects of Misgurnus mizolepis Protein Hydrolysate against Atropine-Induced Dry Eye Disease
WO2017049001A1 (en) Protection and sealing of the ocular surface barrier by clusterin
HK1241379B (zh) 短合成肽及其治疗和/或预防乾眼症的用途
HK1241379A1 (en) Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000